Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

Market Cap	4.40B -11.3%
Revenue (ttm)	892.24M +2.0%
Net Income	178.37M -44.1%
EPS	2.24 -44.4%
Shares Out	77.38M
PE Ratio	25.33
Forward PE	n/a
Dividend	2.00 (3.67%)
Ex-Dividend Date	n/a

Volume	1,359,435
Average Volume	529,633
Open	54.44
Previous Close	54.44
Day's Range	54.31 - 56.97
52-Week Range	53.56 - 78.20
Beta	0.25
RSI	42.64
Earnings Date	Apr 20, 2026

About Hangzhou Alltest Biotech

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; fluorescence immunoassay tests and analyzers; urine analysis solutions, biochemistry reagents, VTM, blood glucose monitoring systems, and HB hemoglobin te...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2009
• Employees: 960
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688606

Financial Performance

In 2025, Hangzhou Alltest Biotech's revenue was 905.34 million, an increase of 4.47% compared to the previous year's 866.58 million. Earnings were 220.19 million, a decrease of -27.20%.